Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €6.70 EUR
Change Today +0.429 / 6.84%
Volume 115.0
GBY On Other Exchanges
GBY is not on other exchanges.
As of 3:08 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

H. Ward Wolff

Chief Financial Officer and Executive Vice President,Sangamo Biosciences Inc.
AgeTotal Calculated CompensationThis person is connected to 17 board members in 2 different organizations across 4 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. H. Ward Wolff has been an Executive Vice President and the Chief Financial Officer of Sangamo Biosciences Inc., since December 2007 and serves as its Principal Accounting Officer. Mr. Wolff oversees Sangamo's administrative, financial and business development activities and operations. He has over 25 years of financial experience. Mr. Wolff served as Chief Financial Officer and Senior Vice President of Finance of Abgenix Inc. from September 13, 2004 to April 2006 ...

Read Full Background

Corporate Headquarters*

501 Canal Boulevard
Richmond, California 94804

United States

Phone: 510-970-6000
Fax: 510-236-8951

Board Members Memberships*

Independent Director and Chairman of Audit Committee
Director and Chairman of Audit Committee


Harvard Business School
University of California Berkeley

Other Affiliations*

Annual Compensation*

Total Annual Compensation$405,000

Stock Options*

Restricted Stock Awards$527,625
Exercised Options90,000
Exercised Options Value$910,720
Exercisable Options894,500
Exercisable Options Value$6,315,895
Unexercisable Options172,500
Unexercisable Options Value$688,725
Total Value of Options$7,915,340
Total Number of Options1,157,000

Total Compensation*

Total Annual Cash Compensation$550,800
Total Short Term Compensation$405,000
Other Long Term Compensation$527,625
Total Calculated Compensation$1,685,768
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GBY:GR €6.70 EUR +0.429


Nick Leschly Chief Executive Officer, President and Director
bluebird bio, Inc.
André Choulika Ph.D.Co-Founder, Chairman and Chief Executive Officer
Cellectis S.A.
David M. Pernock Chairman, Chief Executive Officer and President
Fibrocell Science, Inc.
Jörn Aldag Chief Executive Officer, Managing Director and Member of Management Board
uniQure N.V.
Jeffrey D. Marrazzo M.B.A., M.P.A.Co-Founder, Chief Executive Officer and Director
Spark Therapeutics, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at